This course is part of the Targeted Treatment for Major Depressive Disorder: Focus on Residual Symptoms curriculum.
Podcast
0.50 CME/CE Credit
When SSRIs are Not Enough: Targeting Residual Symptoms in Major Depressive Disorder
In this podcast, expert faculty will discuss how the heterogeneity of major depressive disorder (MDD) symptoms, the frequency of residual symptoms, and the common occurrence of treatment-resistant depression (TRD) indicate a pathophysiology that is complex and multifactorial. The faculty will provide an overview of the current understanding of MDD pathophysiology and discuss how current standard-of-care treatments often fail to comprehensively target these mechanisms, emphasizing how future treatment developments can focus on under-addressed pathophysiological mechanisms, paving the way for personalized MDD treatments that target individual symptom profiles.
Already listened on another platform?
CME/CE Information
0.50 AMA PRA Category 1 Credits™, 0.50 ABIM MOC or 0.41 AANP, including 0.41 AANP Pharm
Release Date: 12/6/2024
Expiration Date: 12/6/2025
Learning Objectives
- Examine the correlation between unresolved, residual symptoms of major depressive disorder (MDD) and underlying pathophysiology not addressed with current standard-of-care treatments
- Explore the neurobiology underpinning anhedonia in MDD and novel agents designed to address it (additional learning objective for accreditation purposes)
- Explore the neurobiology underpinning insomnia in MDD and novel agents designed to address it (additional learning objective for accreditation purposes)
Faculty
Michael Ziffra, MD
Associate Professor
Department of Psychiatry
Northwestern University Feinberg School of Medicine
Jeffrey Rado, MD, MPH, FAPA
Associate Professor, Physician Leader, Collaborative Behavioral Health Program Director, Clinical Trials Research Program, Department of Psychiatry
Behavioral Sciences
Northwestern University Feinberg School of Medicine
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Michael Ziffra, MD: No relevant financial relationships disclosed
Jeffrey Rado, MD, MPH, FAPA (Faculty): Researcher for Neurorelief.
Non-faculty contributors and others involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
Designation Statement
This activity is approved for 0.41 contact hour, which includes 0.41 hour of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Supporters and Partners
Supported by
Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC
Education Partner
Pri-Med Institute
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.